伏诺拉生-四环素双联方案作为幽门螺杆菌感染补救治疗的随机对照试验
本研究为前瞻性开放标签随机对照试验,纳入至少一次根除失败的幽门螺杆菌阳性成人,1:1分配至伏诺拉生-四环素双联方案(VT)或铋剂四联方案(BQT)治疗14天。主要结局为根除率非劣效,VT组与BQT组在改良意向治疗分析中根除率分别为90.6%和89.3%,达到非劣效标准,且VT组不良事件更少、依从性更高。
要点
- VT双联方案14天根除率非劣效于BQT方案。
- VT组治疗中出现的不良事件发生率显著低于BQT组。
- VT组依从性更高,无患者因不良事件停药。
核心结论
- 伏诺拉生-四环素双联方案14天是有效且耐受良好的幽门螺杆菌补救治疗方案。
- 该简化方案根除率非劣效于铋剂四联方案,同时显著减少不良事件并提高依从性。
研究设计与样本
- 前瞻性、开放标签、随机对照试验,纳入至少一次根除失败的幽门螺杆菌阳性成人350例,1:1随机分组。
- VT组给予伏诺拉生20 mg每日两次和四环素500 mg每日三次,BQT组给予兰索拉唑30 mg每日两次、胶体铋150 mg每日三次、四环素500 mg每日三次和甲硝唑400 mg每日三次,疗程均为14天。
关键数值与推荐
- VT双联方案具体剂量:伏诺拉生20 mg每日两次,四环素500 mg每日三次,疗程14天。
临床怎么用
- 对于至少一次幽门螺杆菌根除失败的患者,可考虑使用伏诺拉生-四环素双联方案14天作为补救治疗。
- 该方案不良事件少、依从性高,可能优于铋剂四联方案。
局限性
- 开放标签设计可能引入偏倚。
- 研究纳入人群为至少一次根除失败者,结论外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Treatment of Helicobacter pylori infection after previous eradication failure remains challenging. This study evaluated the efficacy and safety of a vonoprazan-tetracycline (VT) dual regimen as a potential rescue therapy. METHODS: In this prospective, open-label, randomized controlled trial, H pylori-positive adults with at least 1 prior eradication failure were allocated 1:1 to VT dual therapy (vonoprazan [20 mg, twice a day] and tetracycline [500 mg, 3 times a day]), or bismuth quadruple therapy (BQT; lansoprazole [30 mg, twice a day], colloidal bismuth [150 mg, 3 times a day], tetracycline [500 mg, 3 times a day], and metronidazole [400 mg, 3 times a day]) for 14 days. The primary outcome was noninferiority in eradication rates between VT and BQT groups. Secondary outcomes assessed adverse effects in both groups. RESULTS: Of 350 randomized patients (175 per group), the eradication rates in the VT dual-therapy group and the BQT group were, respectively, 90.6% (154 of 170; 95% confidence interval [CI], 84.9%-94.4%) and 89.3% (151 of 169; 95% CI, 83.5%-93.4%) in modified intention-to-treat analysis (difference, 1.2%; 95% CI,-5.7% to 8.2%; noninferiority P = .0003), 91.1% (153 of 168; 95% CI, 85.4%-94.7%) and 92.2% (141 of 153; 95% CI, 86.4%-95.7%) in per-protocol analysis (difference, -1.1%; 95% CI, -7.8% to 5.6%; noninferiority P = .002), meeting the noninferiority criterion (P < .0125). Treatment-emergent adverse events were less frequent with dual therapy (10.9% vs 45.7%; P < .001), and no patient discontinued because of adverse events (0.0% vs 8.6%; P < .001). Adherence was higher with dual therapy (96.0% vs 87.4%; P = .006). CONCLUSIONS: VT dual therapy for 14 days is an effective and well-tolerated rescue regimen for H pylori infection. This simplified regimen achieved eradication rates noninferior to BQT while substantially reducing adverse events and improving adherence. Chinese Clinical Trial Registry: ChiCTR2400080705 (chictr.org.cn,).
引用
- Gao W, Li J, Yang G, et al. Vonoprazan-Tetracycline Dual Regimen as Rescue Therapy for Helicobacter pylori Infection: Randomized Controlled Trial. Gastroenterology. 2026. PMID: 41620038. doi:10.1053/j.gastro.2026.01.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。